Related Experiment Video

Updated: Jun 3, 2026

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma
06:08

Establishment and Characterization of Patient-Derived Xenograft Models of Anaplastic Thyroid Carcinoma and Head and Neck Squamous Cell Carcinoma

Published on: June 2, 2023

Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer

Hiroshi E Takami1

  • 1Department of Surgery, Teikyo University School of Medicine, Tokyo, Japan. takami@med.teikyo-u.ac.jp

Endocrine Journal
|March 9, 2011
PubMed

Insights

Most thyroid cancers have a good prognosis, but certain patients benefit from molecularly targeted drugs. Several targeted therapies, including vandetanib and sorafenib, demonstrate clear clinical utility for specific patient groups.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Thyroid cancer generally has a favorable prognosis.
  • However, a subset of patients may experience disease progression or recurrence.
  • Identifying effective treatment options for these cases is crucial.

Purpose of the Study:

  • To review the clinical utility of specific molecularly targeted drugs in thyroid cancer management.
  • To highlight drugs that offer a good prognosis for patients with specific indications.

Main Methods:

  • Literature review of clinical trials and studies.
  • Analysis of drug efficacy and safety data for targeted therapies.
  • Identification of patient populations who benefit from these treatments.

Main Results:

  • Several molecularly targeted drugs show significant clinical usefulness.
  • Examples include vandetanib, XL-184, sorafenib, motesanib, axitinib, and pazopanib.
  • These agents offer therapeutic options for patients with specific thyroid cancer subtypes or progression.

Conclusions:

  • Molecularly targeted drugs represent a valuable addition to the treatment of select thyroid cancer patients.
  • These therapies can improve outcomes for individuals with specific indications, complementing the generally good prognosis of thyroid cancer.

More Related Videos

Spontaneous Murine Model of Anaplastic Thyroid Cancer05:39

Spontaneous Murine Model of Anaplastic Thyroid Cancer

Published on: February 3, 2023

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma07:01

An Orthotopic Mouse Model of Anaplastic Thyroid Carcinoma

Published on: April 17, 2013

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Synthesis and Regulation of Thyroid Hormones01:20

Synthesis and Regulation of Thyroid Hormones

Low blood levels of the thyroid hormones — triiodothyronine (T3) and thyroxine (T4) — signal the hypothalamus to release the thyrotropin-releasing hormone (TRH). TRH then reaches the pituitary gland and stimulates the release of thyroid-stimulating hormone(TSH) into the bloodstream.
Upon reaching the thyroid gland, TSH stimulates the follicular cells' active uptake of iodide ions from the blood. The ions diffuse to the apical surface of the cells and are oxidized to iodine. The iodine is then...